A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | April 2010 |
| End Date: | March 2012 |
A Phase 1b/2 Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
Study IPI-926-03 is a Phase 1b/2 clinical trial to evaluate IPI 926 in combination with
gemcitabine in patients with previously untreated metastatic pancreatic cancer. Phase 1b is
designed as a dose escalation study. Once the maximum tolerated dose of IPI-926 in
combination with gemcitabine is established in the Phase 1b portion of the study, the Phase
2 portion will commence.
Phase 2 is designed as a randomized, double-blind (investigator/patient), placebo-controlled
study. There is no cross-over option for patients in either arm of the Phase 2 (i.e., there
is no option for patients receiving placebo to cross-over to IPI-926).
IPI 926 is an inhibitor of the Hedgehog Pathway. IPI-926 in combination with gemcitabine
may improve therapeutic outcomes in patients with pancreatic cancer. Infinity is conducting
a Phase 1b/2 clinical trial to evaluate the safety and efficacy of IPI-926 in combination
with gemcitabine in patients with previously untreated metastatic pancreatic cancer.
We found this trial at
6
sites
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
13001 E. 17th Pl.
Aurora, Colorado 80045
Aurora, Colorado 80045
303-724-5000
University of Colorado Cancer Center - Anschutz Cancer Pavilion The University of Colorado Denver |...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials